Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.54 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28818269 | 0.89 | SLC6A4 (0.48) | GBA1SLC6A4HTR2CSLC6A2SLC6A3 | |
| SCHEMBL29889399 | 0.89 | SLC6A4 (0.48) | GBA1SLC6A4HTR2CSLC6A2SLC6A3 | |
| SCHEMBL27850987 | 0.86 | ACHE (0.47) | GBA1SLC6A4SLC6A2LMNACYP2D6 | |
| SCHEMBL3969439 | 0.86 | HTR2C (0.53) | GBA1SLC6A4HTR2CSLC6A2SLC6A3 | |
| Bromide SCHEMBL4039561 | 0.85 | GBA1 (0.49) | GBA1SLC6A4HTR2CSLC6A2SLC6A3 | |
| SCHEMBL19447557 | 0.82 | ACHE (0.44) | — | |
| SCHEMBL3086360 | 0.82 | SLC6A4 (0.55) | GBA1SLC6A4HTR2CSLC6A2SLC6A3 | |
| SCHEMBL23842761 | 0.81 | KMT2A (0.44) | SLC6A4SLC6A2SLC6A3LMNACYP2D6 | |
| SCHEMBL29945214 | 0.81 | ACHE (0.43) | — | |
| SCHEMBL16937323 | 0.81 | ACHE (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-100448846-C | Method for catalytic hydrogenation of acyl pyridine to preparing substituted pyridine compound hydrochlorate | UNIV TSINGHUA (CN) | 2009-01-07 | — | — | CN | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| CN-100413860-C | piperidine derivatives as NMDA receptor antagonists | HUNGARY GIREL GYOGYSZERGYAR (HU) | 2008-08-27 | — | — | CN | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| CN-1556805-A | piperidine derivatives as NMDA receptor antagonists | ������ҩ������˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | GBA1 2652/4885SLC6A4 2513/4885HTR2C 716/4885 |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GBA1 2951/4885SLC6A4 523/4885HTR2C 146/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GBA1 4055/4885SLC6A4 675/4885HTR2C 151/4885 |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | GBA1 4362/4885SLC6A4 570/4885HTR2C 150/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | GBA1 3025/4885SLC6A4 528/4885HTR2C 146/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | GBA1 3991/4885SLC6A4 1341/4885HTR2C 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.